Skip to content

Study · Non-randomized trial · 1996

9 results

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

Eriksson B, Janson ET, Bax ND, Mignon M, Morant R, Opolon P, Rougier P, Oberg KE

Digestion1 Jan 1996Cited by 34 (Europe PMC)

PMID8813476 (opens in a new tab)DOI10.1159/000201402 (opens in a new tab)PepBankPUB-08813476
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated urinary 5-HIAA to 58% of baseline at 3 months.

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced urinary 5-HIAA to 58% of baseline at 3 months.

    Peptide
    Lanreotide
    Outcome
    DecreaseUrinary 5-HIAA at 3 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneous · 3 monthsAs given in this study (human).

    Measurements

    Urinary 5-HIAA at baseline
    444 mumol/day
    13 patients with elevated level; mean
    Urinary 5-HIAA as percent of baseline
    58%
    3 months

    Source sentences

    Summary
    U-5-HIAA, which was elevated in 13 patients with a mean of 444 mumol/day before the start, was reduced to 58% of baseline at 3 months, 68% at 6 months (p = 0.04), 66% at 9 months and 75% at 12 months (p = 0.14).
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  2. 02HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated urinary 5-HIAA to 68% of baseline at 6 months (p = 0.04).

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced urinary 5-HIAA to 68% of baseline at 6 months.

    Peptide
    Lanreotide
    Outcome
    DecreaseUrinary 5-HIAA at 6 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Urinary 5-HIAA at baseline
    444 mumol/day
    13 patients with elevated level; mean
    Urinary 5-HIAA as percent of baseline
    68%
    6 months

    Source sentences

    Summary
    U-5-HIAA, which was elevated in 13 patients with a mean of 444 mumol/day before the start, was reduced to 58% of baseline at 3 months, 68% at 6 months (p = 0.04), 66% at 9 months and 75% at 12 months (p = 0.14).
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  3. 03HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated urinary 5-HIAA to 66% of baseline at 9 months.

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced urinary 5-HIAA to 66% of baseline at 9 months.

    Peptide
    Lanreotide
    Outcome
    DecreaseUrinary 5-HIAA at 9 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneous · 9 monthsAs given in this study (human).

    Measurements

    Urinary 5-HIAA at baseline
    444 mumol/day
    13 patients with elevated level; mean
    Urinary 5-HIAA as percent of baseline
    66%
    9 months

    Source sentences

    Summary
    U-5-HIAA, which was elevated in 13 patients with a mean of 444 mumol/day before the start, was reduced to 58% of baseline at 3 months, 68% at 6 months (p = 0.04), 66% at 9 months and 75% at 12 months (p = 0.14).
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  4. 04HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, urinary 5-HIAA reached 75% of baseline after Somatuline at 12 months (p = 0.14).

    In plain wordsIn neuroendocrine gastrointestinal tumors, urinary 5-HIAA reached 75% of baseline after Somatuline at 12 months, without statistical significance.

    Peptide
    Lanreotide
    Outcome
    No significant changeUrinary 5-HIAA at 12 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Measurements

    U-5-HIAA baseline mean
    444 mumol/day
    elevated in 13 patients, before start
    U-5-HIAA as percent of baseline
    75 % of baseline
    12 months

    Source sentences

    Summary
    U-5-HIAA, which was elevated in 13 patients with a mean of 444 mumol/day before the start, was reduced to 58% of baseline at 3 months, 68% at 6 months (p = 0.04), 66% at 9 months and 75% at 12 months (p = 0.14).
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  5. 05HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated plasma chromogranin to 52% of baseline at 3 months.

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced plasma chromogranin to 52% of baseline at 3 months.

    Peptide
    Lanreotide
    Outcome
    DecreasePlasma chromogranin at 3 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Measurements

    Plasma chromogranin baseline mean
    5300 micrograms/l
    elevated in 18 patients, before start
    Plasma chromogranin as percent of baseline
    52 % of baseline
    3 months

    Source sentences

    Summary
    P-chromogranin was elevated in 18 patients, with a mean of 5,300 micrograms/l before the start, and was reduced to 52, 55, 63 and 64% of the baseline at 3, 6 (p = 0.039), 9 and 12 (p = 0.013) months, respectively.
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  6. 06HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated plasma chromogranin to 55% of baseline at 6 months (p = 0.039).

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced plasma chromogranin to 55% of baseline at 6 months.

    Peptide
    Lanreotide
    Outcome
    DecreasePlasma chromogranin at 6 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Measurements

    Plasma chromogranin baseline mean
    5300 micrograms/l
    elevated in 18 patients, before start
    Plasma chromogranin as percent of baseline
    55 % of baseline
    6 months

    Source sentences

    Summary
    P-chromogranin was elevated in 18 patients, with a mean of 5,300 micrograms/l before the start, and was reduced to 52, 55, 63 and 64% of the baseline at 3, 6 (p = 0.039), 9 and 12 (p = 0.013) months, respectively.
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  7. 07HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated plasma chromogranin to 63% of baseline at 9 months.

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced plasma chromogranin to 63% of baseline at 9 months.

    Peptide
    Lanreotide
    Outcome
    DecreasePlasma chromogranin at 9 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Measurements

    Plasma chromogranin baseline mean
    5300 micrograms/l
    elevated in 18 patients, before start
    Plasma chromogranin as percent of baseline
    63 % of baseline
    9 months

    Source sentences

    Summary
    P-chromogranin was elevated in 18 patients, with a mean of 5,300 micrograms/l before the start, and was reduced to 52, 55, 63 and 64% of the baseline at 3, 6 (p = 0.039), 9 and 12 (p = 0.013) months, respectively.
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  8. 08HumanNon-randomized trialEfficacy outcome

    In neuroendocrine gastrointestinal tumors, Somatuline reduced elevated plasma chromogranin to 64% of baseline at 12 months (p = 0.013).

    In plain wordsIn neuroendocrine gastrointestinal tumors, Somatuline reduced plasma chromogranin to 64% of baseline at 12 months.

    Peptide
    Lanreotide
    Outcome
    DecreasePlasma chromogranin at 12 months
    Study

    n: not reported in source

    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Measurements

    Plasma chromogranin baseline mean
    5300 micrograms/l
    elevated in 18 patients, before start
    Plasma chromogranin as percent of baseline
    64 % of baseline
    12 months

    Source sentences

    Summary
    P-chromogranin was elevated in 18 patients, with a mean of 5,300 micrograms/l before the start, and was reduced to 52, 55, 63 and 64% of the baseline at 3, 6 (p = 0.039), 9 and 12 (p = 0.013) months, respectively.
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.
  9. 09HumanNon-randomized trialEfficacy outcome

    In responding neuroendocrine gastrointestinal tumor patients, Somatuline induced apoptosis.

    In plain wordsIn responding neuroendocrine gastrointestinal tumor patients, Somatuline induced cell death through apoptosis.

    Peptide
    Lanreotide
    Outcome
    IncreaseApoptosis in responders
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    12,000 mg/day in 4 divided injections · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the responding patients, apoptosis was induced.
    1 context sentence
    Summary · context
    In an open pilot phase II study of 19 patients (mean age 58 years), patients were given high dose somatuline with a maintenance dose of 12,000 mg/day in 4 divided s.c. injections.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.